

## LIVE WEBINAR SERIES

Educational presentation followed by time for open discussion/Q&A.

**Quarterly - Beginning July 2023** 

## **Hosted by SWOG Quality Assurance**

Registration (Requires CTEP-IAM Login):

https://swog.exphosted.com/coursepage/85 enUS/ExpertusONE 27

Upcoming 1-Hour Sessions (Choose Your Session):		
Tuesday, July 25, 2023	12:00pm Central	
Thursday, July 27, 2023	4:00pm Central	

For questions, contact Maggie Spillers at mspiller@swog.org.



The following is a brief description of the content of each section contained in a SWOG protocol.

<b>Title page</b> Lists the study number, title, the current	version date, the NCT number,
--	-------------------------------

the agent(s) used in the study and their commercial vs investigational status, the study chairs(s), and statistician(s). In addition, if it is a

registration study, this would also be listed here.

**Protocol Contact Information** Provides contact information for questions about eligibility, data

submission, specimens, medical queries, CTEP-IAM, OPEN, patient

transfers, SAEs, and the CTSU Helpdesk.

Schema Provides a diagrammatic overview of a protocol from registration to the

end of the protocol treatment.

1.0 Objectives States the study purpose, a brief outline of the therapy under evaluation

and the endpoints of interest (survival, response, time to progression, etc.)

2.0 Background Supplies justification for conducting the study and cites results of similar

> studies or pilot data. This section provides a detailed explanation of why it is felt that this approach is potentially better than the current standard of

care.

3.0 Drug Information Describes the drugs used in the study, their known toxicities, storage

requirements, drug stability, administration, and supply information.

CAEPR table with exceptions to SAE reporting (SPEER).

4.0 Staging Criteria When required, this section details staging criteria used in the study.

Diagnostic criteria may also be included in this section, as appropriate.

5.0 Eligibility Criteria Outlines participant and disease characteristics required or excluded for

participation in the study. There are **NO WAIVERS** to these criteria.

6.0 Stratification Factors Stratification factors are pre-treatment participant characteristics which

are balanced across treatment arms. These factors must be documented

PRIOR to randomization.

7.0 Treatment Plan Provides a description of the treatment or study plan, including

> precautions, prohibited medications, pre-medications, dose, schedules, number of cycles, study specific procedures for disease assessment, and reasons for discontinuing treatment. Pre-medication and supportive care

are also included, as appropriate.

8.0 Toxicities Monitored &

Lists the anticipated toxicities and guidelines for dosage adjustment and serious adverse event reporting requirements, including additional events **Dosage Modifications** 

to be reported that fall outside of the reporting requirement tables.



04APR2023 Page 1 of 2



**9.0 Study Calendar**General snapshot of <u>study requirements for all tests, procedures</u>, and treatment administration required while the participant is on study.

10.0 Criteria for Evaluation & Endpoint Definitions

Provides instructions for <u>measuring disease response</u>, participant performance status, and study endpoints.

11.0 Statistical Considerations

Reiterates the study objectives, defines accrual goals and <u>describes the</u> <u>study design</u> used to address the objectives of the study. Guidelines for early closure and data and safety monitoring will also be outlined.

12.0 Discipline Review

Includes information regarding <u>pathology</u>, <u>radiation therapy</u>, <u>imaging or surgery review requirements</u> and, when required, includes details regarding submission of materials.

13.0 Registration Guidelines

Provides detailed <u>patient registration instructions</u> including when and how to register, how many registration steps are required for the study, registration policies, the requirement for the <u>Registration Worksheet</u> to be completed.

14.0 Data Submission Schedule

Provides a detailed <u>schedule for all required data submission</u>, and how to submit them. Generally, source documentation is uploaded in RAVE and radiology scan images are submitted to TRIAD.

**15.0 Special Instructions** 

Outlines other aspects of protocol participation, including special instructions or protocol specific training, specimen shipping or handling procedures or other materials, if applicable.

16.0 Ethical and Regulatory

Describes <u>ethical and regulatory issues</u> for the study. Informed consent, IRB, and drug accountability information are presented.

17.0 Bibliography

Lists references used in the protocol.

18.0 Appendices

Contain all appendices referenced in the text. Examples of Appendices:

- Instructions for the SWOG Biospecimen Bank
- Participant Diaries
- Quality Assurance Audit/Monitoring plans
- New York Heart Association Criteria
- Drug Interaction Examples
- Live Vaccine Examples
- Participant Drug Information Handout and Wallet Card
- Algorithms for Immune Related Reactions



04APR2023 Page 2 of 2



## PROTOCOL CONTACT INFORMATION

Regulatory, Protocol, Informed Consent:	protocols@swog.org	
Medical Queries/Dose Modifications	Email the contact(s) listed in Protocol Section 8 or Study Chairs.	
Specimen Tracking System/CRA Workbench:	technicalquestion@crab.org	
CTEP-IAM:	https://ctepcore.nci.nih.gov/iam/index.jsp	
OPEN:	888-823-5923 or ctsucontact@westat.com	
Patient Transfers:	patienttransfer@crab.org	
AEs/SAEs:	adr@swog.org	
Quality Assurance/Audits:	qamail@swog.org	
Eligibility, RAVE, and Data Submission: SWOG Data Operations Center: 206-652-2267	<ul> <li>breastquestion@crab.org</li> <li>cancercontrolquestion@crab.org</li> <li>giquestion@crab.org</li> <li>guquestion@crab.org</li> <li>leukemiaquestion@crab.org</li> <li>LUNGMAPquestion@crab.org</li> <li>lungquestion@crab.org</li> <li>lymphomaquestion@crab.org</li> <li>melanomaquestion@crab.org</li> <li>myelomaquestion@crab.org</li> <li>raretumors@crab.org</li> <li>SWOGComboMATCHQuestion@crab.org</li> <li>For MyeloMATCH and iMATCH protocols, re-</li> </ul>	



## TRAINING RESOURCES

SWOG Learning  Management System <a href="https://swog.exphosted.com">https://swog.exphosted.com</a>	<ul><li>Clinical Trials Training Course</li><li>Live Webinars</li><li>Head CRA Training</li><li>Central Monitoring</li></ul>	<ul><li>Regulatory Workshops</li><li>APP Workshops</li><li>Investigational Agents</li><li>TeamScience Training</li></ul>
SWOG Website <a href="https://www.swog.org">https://www.swog.org</a>	<ul><li>FAQs</li><li>Quality Assurance/Audits</li><li>SWOG Policies</li></ul>	<ul><li>Clinical Research Resources</li><li>SAE Resources</li><li>Continuing Education</li></ul>
SWOG CRA Workbench  https://txwb.crab.org/TXWB/  Logon.aspx	<ul><li> Tools of the Trade</li><li> CRA Newsletter</li><li> Best Practices</li></ul>	<ul><li> CRA Manual</li><li> Your First Group Meeting</li><li> SWOG Glossary</li></ul>
CTSU CLASS  Learning Management System <a href="https://classlms.org/#/">https://classlms.org/#/</a> <a href="mailto:dashboard">dashboard</a>	<ul><li>Study-Specific Training</li><li>RECIST Training</li><li>Source Document Portal</li></ul>	<ul><li>Neuropen Training</li><li>Tuning Fork Training</li><li>Timed Get Up and Go</li></ul>
NCI Pharmaceutical  Management Branch <a href="https://ctep.cancer.gov/">https://ctep.cancer.gov/</a> branches/pmb/default.htm	<ul><li>Ordering Agents</li><li>DARF Training</li><li>AURORA Training</li></ul>	<ul><li>Agent Storage</li><li>Local Agent Destruction</li><li>Agent Returns/Transfers</li></ul>